IMVARIA has launched Fibresolve, a groundbreaking AI Biomarker designed for the detection of lung fibrosis, particularly focusing on idiopathic pulmonary fibrosis (IPF).
This digital biomarker solution utilises artificial intelligence to assist clinicians in safely and non-invasively diagnosing lung fibrosis and providing subtype classification, potentially enabling earlier initiation of appropriate treatments.
Lung fibrosis encompasses a group of life-threatening diseases affecting a significant number of individuals annually, with IPF being particularly devastating. Conventional therapies for this condition are costly and may pose risks if administered to inappropriate patients.
On average, there is a delay of nearly two-and-a-half years between the onset of symptoms and diagnosis of this condition. However, severe lung impairment and even death can occur within one to two years after the onset of lung fibrosis.
The FDA's approval of Fibresolve brings fresh hope to individuals struggling with the rapidly deteriorating symptoms of this rare yet lethal disease. Furthermore, it arms healthcare professionals caring for these patients with a powerful new tool, designed to improve the preservation of lives and relief of suffering at a pace made possible only through AI technology.
